MedTrace Logo

Study to Evaluate the Safety, Tolerability, and Efficacy of BGE-175 in Hospitalized Adults With Coronavirus Disease 2019 (COVID-19) That Are Not in Respiratory Failure

NCT04705597 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 194

Last updated 2023-07-03

Study results available
· View outcomes & findings →

Summary

The primary objectives of this study are to evaluate the safety, tolerability, and efficacy of BGE-175 in participants ≥ 50 years of age hospitalized with documented COVID-19.

Conditions

  • Covid19

Interventions

DRUG

BGE-175

Drug

OTHER

Placebo

Placebo

Sponsors & Collaborators

  • BioAge Labs, Inc.

    lead INDUSTRY

Principal Investigators

  • Richard G Wilkerson, MD · University of Maryland, Baltimore

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-18
Primary Completion
2022-04-20
Completion
2022-05-19
FDA Drug
Yes

Countries

  • United States
  • Argentina
  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04705597 on ClinicalTrials.gov